nach oben

Diabetologia

Erschienen in:

01.06.2011 | Article

Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans

verfasst von: B. Meissburger, L. Stachorski, E. Röder, G. Rudofsky, C. Wolfrum

Erschienen in: Diabetologia | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Extracellular matrix reorganisation is a crucial step of adipocyte differentiation and is controlled by the matrix metalloproteinase–tissue inhibitor of matrix metalloproteinase (TIMP) enzyme system. We therefore sought to define the role of TIMP1 in adipogenesis and to elucidate whether upregulation of TIMP1 in obesity has direct effects on adipocyte formation.

Methods

TIMP1 protein levels and mRNA were measured in lean and obese mice with a focus on levels in adipose tissue. We also analysed the effect of recombinant murine TIMP1 on adipogenesis, adipocyte size and metabolic control in vitro and in vivo.

Results

TIMP1 levels were increased in the serum and adipose tissue of obese mouse models. Recombinant murine TIMP1 inhibited adipocyte differentiation in 3T3-L1 as well as in subcutaneous primary pre-adipocytes. Conversely, neutralising TIMP1 with a specific antibody enhanced adipocyte differentiation. In vivo, injection of recombinant TIMP1 in mice challenged with a high-fat diet led to enlarged adipocytes. TIMP1-treated mice developed an impaired metabolic profile with increased circulating NEFA levels, hepatic triacylglycerol accumulation and accelerated insulin resistance. Altered glucose clearance in TIMP1-injected mice was due to changes in adipose tissue glucose uptake, whereas muscle glucose clearance remained unaffected.

Conclusions/interpretation

TIMP1 is a negative regulator of adipogenesis. In vivo, TIMP1 leads to enlarged adipocytes in the state of overnutrition. This might contribute to the detrimental metabolic consequences seen in TIMP1-injected mice, such as systemic fatty acid overload, hepatic lipid accumulation and insulin resistance.

Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8:200PubMedCrossRef

Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef

Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 356:213–215PubMedCrossRef

Goossens GH (2008) The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 94:206–218PubMedCrossRef

Sethi JK, Vidal-Puig AJ (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 48:1253–1262PubMedCrossRef

Jo J, Gavrilova O, Pack S et al (2009) Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 5:e1000324PubMedCrossRef

Spalding KL, Arner E, Westermark PO et al (2008) Dynamics of fat cell turnover in humans. Nature 453:783–787PubMedCrossRef

Salans LB, Doughert JW (1971) Effect of insulin upon glucose metabolism by adipose cells of different size—influence of cell lipid and protein content, age, and nutritional state. J Clin Invest 50:1399PubMedCrossRef

Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, Eriksson JW (2007) Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 50:625–633PubMedCrossRef

10.

Gregoire FM (2001) Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Medicine (Maywood) 226:997–1002

11.

Gesta S, Tseng Y, Kahn CR (2007) Developmental origin of fat: tracking obesity to its source. Cell 131:242–256PubMedCrossRef

12.

Aratani Y, Kitagawa Y (1988) Enhanced synthesis and secretion of type IV collagen and entactin during adipose conversion of 3T3-L1 cells and production of unorthodox laminin complex. J Biol Chem 263:16163–16169PubMed

13.

Kubo Y, Kaidzu S, Nakajima I, Takenouchi K, Nakamura F (2000) Organization of extracellular matrix components during differentiation of adipocytes in long-term culture. In Vitro Cell Dev Biol Anim 36:38–44PubMedCrossRef

14.

Weiner FR, Shah A, Smith PJ, Rubin CS, Zern MA (1989) Regulation of collagen gene expression in 3T3-L1 cells. Effects of adipocyte differentiation and tumor necrosis factor alpha. Biochemistry 28:4094–4099PubMedCrossRef

15.

Spiegelman BM, Ginty CA (1983) Fibronectin modulation of cell shape and lipogenic gene expression in 3T3-adipocytes. Cell 35:657–666PubMedCrossRef

16.

Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ (2006) A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125:577–591PubMedCrossRef

17.

Lilla J, Stickens D, Werb Z (2002) Metalloproteases and adipogenesis: a weighty subject. Am J Pathol 160:1551–1554PubMedCrossRef

18.

Chavey C, Mari B, Monthouel MN et al (2003) Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 278:11888–11896PubMedCrossRef

19.

Lijnen HR, Van HB, Frederix L, Rio MC, Collen D (2002) Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity. Thromb Haemost 87:530–535PubMed

20.

Maquoi E, Demeulemeester D, Voros G, Collen D, Lijnen HR (2003) Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation. Thromb Haemost 89:696–704PubMed

21.

Pendas AM, Folgueras AR, Llano E et al (2004) Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 24:5304–5313PubMedCrossRef

22.

Alexander CM, Selvarajan S, Mudgett J, Werb Z (2001) Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 152:693–703PubMedCrossRef

23.

Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z (2001) A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol 3:267–275PubMedCrossRef

24.

Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D (2002) Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol 22:374–379PubMedCrossRef

25.

Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803:55–71PubMedCrossRef

26.

Kralisch S, Bluher M, Tonjes A et al (2007) Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol Eur Fed Endocr Soc 156:257–261

27.

Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E (2003) Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost 89:249–255PubMed

28.

Gerin I, Louis GW, Zhang X et al (2008) Hyperphagia and obesity in female mice lacking tissue inhibitor of metalloproteinase-1. Endocrinology 150:1697–1704PubMedCrossRef

29.

Demeulemeester D, Scroyen I, Voros G et al (2006) Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost 95:1019–1024PubMed

30.

Hansen LH, Madsen B, Teisner B, Nielsen JH, Billestrup N (1998) Characterization of the inhibitory effect of growth hormone on primary preadipocyte differentiation. Mol Endocrinol 12:1140–1149PubMedCrossRef

31.

Carpenter AE, Jones TR, Lamprecht MR et al (2006) Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7:R100PubMedCrossRef

32.

Chen HC, Farese RV Jr (2002) Determination of adipocyte size by computer image analysis. J Lipid Res 43:986–989PubMed

33.

Zisman A, Peroni OD, Abel ED et al (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6:924–928PubMedCrossRef

34.

Permana PA, Nair S, Lee YH, Luczy-Bachman G, de Courten BV, Tataranni PA (2004) Subcutaneous abdominal preadipocyte differentiation in vitro inversely correlates with central obesity. Am J Physiol Endocrinol Metab 286:E958–E962PubMedCrossRef

35.

Wolfrum C, Luca E, Stoffel M (2004) Role of foxa2 in the regulation of hepatic glucose and fatty acid metabolism in starvation and in diabetes. Diabetes 53:A5–A5

36.

Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M (2001) Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50:2080–2086PubMedCrossRef

37.

Klimcakova E, Moro C, Mazzucotelli A et al (2007) Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem Biophys Res Commun 358:897–902PubMedCrossRef

38.

Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR (2002) Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 51:1093–1101PubMedCrossRef

39.

Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM (2007) Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol 293:E656–E665

40.

Bourlier V, Zakaroff-Girard A, De Barros S et al (2005) Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 312:1272–1279PubMedCrossRef

41.

Van Hul M, Lijnen HR (2008) A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 6:1198–1206PubMedCrossRef

42.

Andarawewa KL, Motrescu ER, Chenard MP et al (2005) Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res 65:10862–10871PubMedCrossRef

43.

Chesler L, Golde DW, Bersch N, Johnson MD (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86:4506–4515PubMed

44.

Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738PubMedCrossRef

45.

Joe AW, Yi L, Even Y, Vogl AW, Rossi FM (2009) Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem Cells 27:2563–2570PubMedCrossRef

46.

Buren J, Lindmark S, Renstrom F, Eriksson JW (2003) In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism 52:239–245PubMedCrossRef

47.

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE (2000) Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43:1498–1506PubMedCrossRef

48.

Stienstra R, Duval C, Muller M, Kersten S (2007) PPARs, obesity, and inflammation. PPAR Res 2007:95974PubMed

49.

Zeyda M, Stulnig TM (2009) Obesity, inflammation, and insulin resistance—a mini-review. Gerontology 55:379–386PubMedCrossRef

50.

Kralisch S, Klein J, Lossner U et al (2005) Proinflammatory adipocytokines induce TIMP-1 expression in 3T3-L1 adipocytes. FEBS Lett 579:6417–6422PubMedCrossRef

51.

Weise S, Kralisch S, Sommer G et al (2008) Tissue inhibitor of metalloproteinase-1 mRNA production and protein secretion are induced by interleukin-1 beta in 3T3-L1 adipocytes. J Endocrinol 198:169–174PubMedCrossRef

52.

Wolfrum C, Shih DQ, Kuwajima S, Norris AW, Kahn CR, Stoffel M (2003) Role of Foxa-2 in adipocyte metabolism and differentiation. J Clin Invest 112:345–356PubMed

Titel: Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans
verfasst von: B. Meissburger
L. Stachorski
E. Röder
G. Rudofsky
C. Wolfrum
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2093-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway

Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes

No effect by the common gene variant rs10830963 of the melatonin receptor 1B on the association between sleep disturbances and type 2 diabetes: results from the Nord-Trøndelag Health Study

Amelioration of lipid-induced insulin resistance in rat skeletal muscle by overexpression of Pgc-1β involves reductions in long-chain acyl-CoA levels and oxidative stress

Erratum to: Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways